摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3aS,4R,7aR)-2,2-dimethylhexahydro-1,3-benzodioxol-4-amine | 1207201-29-3

中文名称
——
中文别名
——
英文名称
(3aS,4R,7aR)-2,2-dimethylhexahydro-1,3-benzodioxol-4-amine
英文别名
(3aS,4R,7aR)-2,2-dimethylhexahydrobenzo-1,3-dioxol-4-yl-amine;(3aS,4R,7aR)-2,2-dimethyl-3a,4,5,6,7,7a-hexahydro-1,3-benzodioxol-4-amine
(3aS,4R,7aR)-2,2-dimethylhexahydro-1,3-benzodioxol-4-amine化学式
CAS
1207201-29-3
化学式
C9H17NO2
mdl
——
分子量
171.239
InChiKey
KCYMQDIICGORAY-PRJMDXOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    235.5±30.0 °C(Predicted)
  • 密度:
    1.014±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    44.5
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • INHIBITORS OF SPHINGOSINE KINASE
    申请人:Stieber Frank
    公开号:US20120252789A1
    公开(公告)日:2012-10-04
    The present invention relates to compounds of the formula (I), in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , M 1 , M 2 , M 3 , M 4 , Y 1 , Y 2 , V, W, n, m and o have the meanings given in Claim 1 , and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use in the treatment of diseases which are influenced by inhibition of Sph kinase 1.
    本发明涉及式(I)的化合物,其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、M1、M2、M3、M4、Y1、Y2、V、W、n、m和o具有权利要求1中给出的含义,以及其生理上可接受的盐、衍生物、前药、溶剂合物、互变异构体和立体异构体,包括所有比例的混合物,用于治疗受Sph激酶1抑制影响的疾病。
  • Novel Phenylamino Isonicotinamide Compounds
    申请人:Goutopoulos Andreas
    公开号:US20110184032A1
    公开(公告)日:2011-07-28
    The invention provides novel compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation.
    该发明提供了公式(I)的新化合物,其制备和用于治疗高增殖性疾病,如癌症、再狭窄和炎症。
  • Phenylamino isonicotinamide compounds
    申请人:Goutopoulos Andreas
    公开号:US08404725B2
    公开(公告)日:2013-03-26
    The invention provides novel substituted phenylamino isonicotinamide compounds (I), pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein X, R1, R2, R3, R4, R5 and R6 are as defined in the specification. Said compounds are MEK inhibitors useful in the treatment of hyperproliferative diseases related to the hyperactivity of MEK, such as restenosis, as well as diseases modulated by the MEK cascade, such as cancer and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
    本发明提供了新型取代苯氨基异烟酰胺化合物(I),其药物可接受的盐,溶剂或前药,其中X、R1、R2、R3、R4、R5和R6如规范中所定义。所述化合物是MEK抑制剂,可用于治疗与MEK的高活性相关的高增殖性疾病,如再狭窄,以及受MEK级联调节的疾病,如癌症和炎症。还公开了这种化合物在哺乳动物,特别是人类的高增殖性疾病治疗中的应用,以及含有这种化合物的制药组合物。
  • Inhibitors of sphingosine kinase
    申请人:Stieber Frank
    公开号:US09062015B2
    公开(公告)日:2015-06-23
    The present invention relates to compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, M1, M2, M3, M4, Y1, Y2, V, W, n, m and o have the meanings given in Claim 1, and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use in the treatment of diseases which are influenced by inhibition of Sph kinase 1.
    本发明涉及公式(I)的化合物,其中R1,R2,R3,R4,R5,R6,R7,R8,R9,R10,R11,R12,R13,R14,R15,R16,R17,M1,M2,M3,M4,Y1,Y2,V,W,n,m和o具有权利要求书中所给出的含义,并且其生理上可接受的盐,衍生物,前药,溶剂化物,互变异构体和立体异构体,包括所有比例的混合物,用于治疗受Sph激酶1抑制影响的疾病。
  • METHOD FOR THE PREPARATION OF CIS-1,2-DIOLS IN THE KILOGRAM SCALE
    申请人:Mederski Werner
    公开号:US20130102640A1
    公开(公告)日:2013-04-25
    The present invention relates to the scale up of the preparation of cis-1,2-diols of formula I from the gram to the kilogram scale.
    本发明涉及从克到千克规模的cis-1,2-二醇的制备放大。
查看更多